Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma

Clinical Lymphoma

Volumn 4, Issue 3, 2003, Pages 176-178

  DiVenuti, Gina ^a   Nawgiri, Rangana ^a   Foss, Francine ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Hematopoiesis; Interleukin 2 receptor; Myelofibrosis

Indexed keywords

BEXAROTENE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER GROWTH; CANCER REGRESSION; CASE REPORT; CLINICAL FEATURE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LEUKEMIA CELL; LEUKOCYTOSIS; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MYELOFIBROSIS; PARACRINE SIGNALING; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA;

EID: 1642545477     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.027     Document Type: Article

References (26)

1. Manns A, Cleghorne F, Falk RT, et al. Role of HTLV-1 in development of non-Hodgkin lymphoma in Jamaica and Trinidad and Tobago. The HTLV Lymphoma Study Group. Lancet 1993; 342:1447-1450.
2. Tajima K, Hinuma Y. Epidemiology of HTLV-I/II in Japan and the world. In: Takatsuki K, Hinuma Y, Yoshida M, eds. Advances in adult T-cell leukemia and HTLV-1 research. Tokyo: Japan Scientific Societies Press, 1992:129-149.
3. Braunwald E, Fauci AS, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine, 15th ed. New York, NY: McGraw-Hill, 2001.
4. Kikuchi M, Jaffe ES, Ralfkiaer E. Adult T-cell leukaemia/lymphoma. In: Jaffe ES Harris NL, Vardiman JW, et al, eds. Pathology and Genetics of Tumours of the Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001:200-203.
5. Bunn PA, Schechter GP, Jaffe E, et al. Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 1983; 309:257-264.
6. Broder SB, Bunn PA, Jaffe E, et al. T-cell lymphoprolifelative syndrome associated with human t-cell leukemia/lymphoma virus. Ann Intern Med 1984; 100:543-557.
7. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376-388.
8. Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998; 39:63-73.
9. Waldmann TA, Goldman CK, Bongiovanni KF, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotropic virus I-induced adult T-cell leukemia. Blood 1993; 82:1701-1712.
10. Bacha PA, Forte SE, McCarthy DM, et al. Impact of interleukin-2-receptor-targeted cytotoxins on a unique model of murine interleukin-2-receptor-expressing malignancy. Int J Cancer 1991; 49:96-101.
11. Bacha P, Williams DP, Waters C, et al. Interleukin 2 receptor-targeted cytotoxicity: interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988; 167:612-622.
12. Moya M, Dautry-Varsat A, Goud B, et al. Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin. J Cell Biol 1985; 101:548-559.
13. Morris RE, Gerstein AS, Bonventre PF, et al. Receptor-mediated entry of diphtheria toxin into monkey kidney (Vero) cells: electron microscopic evaluation. Infect Immun 1985; 50:721-727.
14. Fuchs R, Schmid S, Mellman I. A possible role for Na+-K+ ATPase in regulating ATP-dependent endosome acidification. Proc Natl Acad Sci U S A 1989; 86:539-545.
15. Kagan BL, Finkelstein A, Colombini M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc Natl Acad Sci U S A 1981; 78:4950-4954.
16. Donovan JJ, Simon MI, Draper RK, et al. Diphtheria toxin forms transmembrane channels in planar lipid bilayers. Proc Natl Acad Sci U S A 1981; 78:172-176.
17. Nawata H, Maeda Y, Sumimoto Y, et al. A mechanism of apoptosis induced by all-trans retinoic acid on adult T-cell leukemia cells: a possible involvement of the Tax/NF-kappaB signaling pathway. Leuk Res 2001; 25:323-331.
18. Re GG, Waters C, Poisson L, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. Cancer Res 1996; 56:2590-2595.
19. Otawa M, Kawanishi Y, Ando K, et al. [Rapidly progressive fibrosis and increased CD68-positive cells in the bone marrow at the terminal stage of adult T-cell leukemia accompanied by polycythemia vera]. Rinsho Ketsueki 2000; 41:1254-1259.
20. Masutani K, Fujimaru M, Tsubota Y, et al. [Double negative adult T-cell leukemia with hemophagocytic syndrome]. Rinsho Ketsueki 1997; 38:1199-1205.
21. Inoue D, Santiago P, Horne WC, et al. Identification of an osteoclast transcription factor that binds to the human T cell leukemia virus type I-long terminal repeat enhancer element. J Biol Chem 1997; 272:25386-25393.
22. Ruddle NH, Li CB, Horne WC, et al. Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover. Virology 1993; 197:196-204.
23. Araki K, Harada K, Nakamoto K, et al. Clinical Significance of serum soluble IL-2R levels in patients with adult T cell leukemia and HTLV-1 carriers. Clin Exp Immunol 2000; 119:259-263.
24. Wang J, Wang A. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Br J Hematol 1994; 86:380-382.
25. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia/lymphoma. Curr Treat Options Oncol 2001; 2:291-300.
26. Dimopoulos MA, Weber D, Kantarjian H, et al. HyperCVAD for VAD-resistant multiple myeloma. Am J Hematol 1996; 52:77-81.